We are currently going crazy trying to get ready for the Society for Neuroscience meeting which will be held in Washington DC from 15th to 19th of November. The home page for the meeting is here. This will be the second time we have hosted a booth at this major international meeting, and we are looking forward to the numerous social, scientific and commercial interactions which always take place at these meetings.
The new website now seems to be working reasonably well now. We are adding product details and linking our product datasheets to each product, which will take a little more work. Note that you can now order prints of our large high resolution images on line, and we have several new antibodies including a panel of mouse monoclonals to Aurora kinases A, B and C. Since these three kinases are very closely related we characterized each clone an all three proteins, and as a result have monoclonal reactive with only one of the three kinases as well as monoclonals which bind to all three. For more specific details see our blog post here.
You should now be able to see our new website! We are sure there will be a few problems with this which should get sorted out quickly we hope. Also, we have several new products including new antibodies to tubulin which can be used in immunocytochemical studies and as western blotting standards, and also specific antibodies to Aurora B kinase, an enzyme important in the regulation of cell division. These antibodies do not cross-react with the very similar Aurora A and C kinases. Details of these will be posted in the next few days.
We continue to produce peer reviewed publications in which we have generated novel antibodies or used our antibody based assays in collaborative research studies. For example Gresle et al. 2014, Jokubatis et al. 2013 and Talla et al. 2013 describe the use of our pNF-H-ELISA in the detection of axonal loss from blood samples in a variety of damage and disease states. In another example, Rutherford et al. 2013 describes the generation and use of novel antibodies to ubiquilin 2. We will continue to perform such collaborations and generate more such data in future.